65,437 trials
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Eosinophilic Esophagitis
Primary: Sensitivity of Patch Testing — 1 Participants
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
Degenerative Disc Disease · Spinal Stenosis · Spondylolisthesis
Primary: Number of Patients With Fusion — 16 Participants
Overweight
Primary: Body Weight After Intervention — -2.11; -3.7 Kg
Psoriasis
Primary: proSPI (s) at Week 16 Compared to Baseline — 24.89; 2.34 scores on a scale — p=<0.0001
Alopecia Areata
Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Renal Transplantation
Primary: Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (INF) of Belatacept. — 17084539; 21579398 ng.h/mL
Acute, Perforated Appendicitis
Primary: Number of Participants With Postoperative Intra-abdominal Abscess — 6; 8 Participants
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Harvey Bradshaw Index — 3.7; 3.2; 4.2 units on a scale
Crisis Intervention · Suicide and Depression
Primary: Number of Participants Reporting Use of Crisis-referrals — 130; 159 Participants — p==.02
Ovarian Cancer
Primary: Progression-free Survival — 20.4; 23.2 percentage of participants
Colorectal Adenomatous Polyps
Primary: Number of Participants With Conventional Adenoma and Sessile Serrated Adenoma/Polyp Detected — 208; 171 Participants
Pulmonary Function; Newborn, Abnormal · Infant Wheeze · In-utero Nicotine
Primary: Forced Expiratory Flow at 75% of Expired Volume (FEF75) — 188.7; 200.7 ml/s — p=0.19